HEMATOPOIESIS AND HEMATOLOGICAL MALIGNANCIES

项目概述（见说明）：造血和血液恶性肿瘤（HHM）项目是一个综合和合作的项目，有来自3个部门的28名成员。项目成员得到同行评审资金（直接成本）4,515,551美元的支持，其中1,113,418美元来自NCI。项目成员共有292篇同行评审出版物，其中21%为项目内出版物，13%为项目间出版物。HHM项目的总体目标是：1)促进参与血液系统恶性肿瘤临床管理和生物学研究的研究人员之间的科学互动；2)促进转化研究，促进实验室研究向这些疾病患者管理的转移；3)促进芝加哥大学综合癌症中心和合作部门资源的优化利用。恶性血液病的细胞遗传学和分子分析已经鉴定出许多参与正常造血的基因，以及白血病、淋巴瘤、骨髓增生性疾病和多发性骨髓瘤的发病机制。这些见解改进了诊断和预后能力，并为适应风险的分子靶向治疗提供了基础。该计划的成员在确定导致血液恶性肿瘤发展的发病事件方面发挥了重要作用。这些重要的见解已经开始转化为新的分子靶向治疗方法。HHM项目由一组紧密结合的研究人员组成，他们通过共同的研究主题联系在一起，并努力实现共同的目标。具体而言，HHM项目研究人员的三个主要研究主题是：1)通过分析正常造血和恶性疾病发展的分子遗传学来研究正常和恶性造血的机制；2)生成和分析模型系统，以解剖对正常造血和造血疾病发展至关重要的基因的功能；3)将这些见解转化为血液系统恶性肿瘤的新型风险适应临床试验的设计和实施。

PROJECT SUMMARY (See instructions): The Hematopoiesis and Hematological Malignancies (HHM) Program is an integrated and collaborative program with 28 members from 3 Departments. Program members are supported by $ 4,515,551 in peer reviewed funding (direct costs), with $ 1,113,418 from the NCI. Program members have a total of 292 peer-reviewed publications, including 21% intraprogrammatic and 13% interprogrammatic publications. The overall goals of the HHM Program are: 1) to foster scientific interactions among investigators involved in clinical management and biological studies of hematological malignancies; 2) to promote translational research and facilitate the transfer of laboratory research to the management of patients with these diseases; and 3) to promote optimal use of resources within the University of Chicago Comprehensive Cancer Center and collaborating departments. Cytogenetic and molecular analyses of hematological malignancies have led to the identification of many genes that are involved in normal hematopoiesis, as well as in the pathogenesis of leukemia, lymphoma, myeloproliferative disorders, and multiple myeloma. These insights have refined diagnostic and prognostic capabilities, and have provided the foundation for risk-adapted, molecularly targeted therapeutics. Members of this Program have had major roles in defining the pathogenetic events leading to the development of hematological malignancies. These important insights have begun to be translated into novel molecularly targeted treatment approaches. The HHM Program is comprised of a tightly integrated group of investigators who are linked by common research themes and are working towards achievement of common goals. Specifically, the three primary research themes of the investigators in the HHM Program are: 1) to investigate mechanisms of normal and malignant hematopothesis by analyzing the molecular genetics of normal hematopothesis and the development of malignant diseases; 2) to generate and analyze model systems to dissect the functions of genes that are critical to normal hematopoiesis and to the development of hematopoietic diseases; and 3) to translate these insights into the design and conduct of novel risk-adapted clinical trials in hematological malignancies.